28 research outputs found
The bacterial community structure in an alkaline saline soil spiked with anthracene
Background: The application of polycyclic aromatic hydrocarbons (PAHs)
will affect the bacterial community structure as some groups will be
favoured and others not. An alkaline saline soil with electrolytic
conductivity (EC) 56 dS m-1 was spiked with anthracene and acetone
while their effect on bacterial community structure was investigated.
Results: The percentages of Acidobacteria and Actinobacteria decreased
over time, while the percentage of Proteobacteria, mostly
Xanthomonadales, increased. The percentage of the phylotypes belonging
to the Nocardioides , Rhodococcus and Streptomyces , known
degraders of PAHs, was larger in the anthracene-amended soil than in
the acetone-amended and unamended soil at day 14. The phylotypes
belonging to the genera Sphingomonas , also a known degrader of PAHs,
however, was lower. Weighted and unweighted PCoA with UniFrac indicated
that phylotypes were similar in the different treatments at day 0, but
changed at day 1. After 14 days, phylotypes in the unamended and
acetone-amended soil were similar, but different from those in the
anthracene-spiked soil. Conclusions: It was found that incubating the
soil and contaminating it with anthracene changed the bacterial
community structure, but spiking the soil with acetone had little or no
effect on the bacterial community structure compared to the unamended
soil
Autotransfusi\uf3n en intervenciones quir\ufargicas electivas
A quince (15) pacientes con edades comprendidas entre 21 a 50 a\uf1os, Radiograf\ueda
de t\uf3rax, electrocardiograma, tiempo de sangr\ueda y coagulaci\uf3n normales y hemoglobina mayor de 12 grs.%/dl, que iban a ser sometidos a Cirug\ueda electiva,
se les practic\uf3 autotransfusi\uf3n sangu\uednea durante el acto operatorio.
Las p\ue9rdidas sangu\uedneas en ninguno de los casos lleg\uf3 al 20% de la volemia calculada, por 10 que no fue necesario transfundirlo con sangre hom\uf3loga.
No se registraron complicaciones y el hematocrito no lleg\uf3 a descender por debajo de 30%, por lo que nunca se comprometi\uf3 el transporte de ox\uedgeno.
Se recomienda el uso de autotransfusi\uf3n en pacientes adultos sin anemia,
insuficiencia mioc\ue1rdica, coronariopat\ueda isqu\ue9mica o enfermedad pulmonar obstructiva
pre-existentes, que vayan a ser sometidos a cirug\ueda electiva donde se esperan p\ue9rdidas sangu\uedneas menores al 20% de la volemia calculada
Hongos asociados con el declinamiento de la manzanita Arctostaphylos pungens HBK en la Sierra Fr\ueda de Aguascalientes, M\ue9xico
Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys
Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry.
BACKGROUND:
The natural history of venous thromboembolism (VTE) in patients with dementia has not been thoroughly studied.
METHODS:
We used the RIETE Registry data to assess the clinical characteristics, treatment strategies and outcome during the first 3 months after acute VTE in all immobilized patients with dementia.
RESULTS:
As of August 2011, 37988 patients had been enrolled, of whom 1316 (3.5%) had dementia. Most patients in both subgroups were initially treated with low-molecular-weight heparin (LMWH). Then, 48% of patients with dementia and 25% of those without dementia received LMWH as long-term therapy. During the first 3 months of anticoagulant therapy, patients with dementia had a higher incidence of fatal pulmonary embolism (PE): 4.0% vs. 1.2% (odds ratio: 3.3; 95% CI: 2.5-4.4) and fatal bleeding: 1.4% vs. 0.5% (odds ratio: 2.9; 95% CI: 1.8-4.6) than those without dementia. In demented patients initially presenting with PE, the incidence of fatal PE during the first week outweighed that of fatal bleeding (42 vs. 4 deaths), but from Day 8, the incidence of fatal PE was similar to the incidence of fatal bleeding. In patients initially presenting with deep vein thrombosis (DVT), there were 4 fatal PE and 8 fatal bleeding events.
CONCLUSIONS:
VTE patients with dementia had a high incidence of fatal PE and fatal bleeding. In those initially presenting with PE, the risk of dying of PE far outweighed that of fatal bleeding. In patients presenting with DVT alone, the risk of fatal PE was lower than that of fatal bleeding
Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis
BACKGROUND:
The risk of patients dying of pulmonary embolism (PE) or bleeding during the treatment of deep vein thrombosis (DVT), and whether these risks are influenced by patient age, has not been thoroughly studied.
METHODS:
We used data from the Registro Informatizado de la Enfermedad TromboEmb\uf3lica (RIETE) to assess the risk of fatal PE and fatal bleeding in 16,199 patients with lower limb DVT (without symptomatic PE at the time of inclusion) during the 3 months after diagnosis, with patients categorized according to age.
RESULTS:
During the 3 months of anticoagulant treatment, there were 31 fatal PEs (0.19%) and 83 fatal hemorrhages (0.51%). During the first 7 days of therapy, the frequency of fatal PEs was similar to that of fatal bleeding (12 vs 14 deaths, respectively; odds ratio [OR], 0.86; 95% confidence interval [CI], 0.39-1.87). However, from days 8 to 90, the frequency of fatal bleeding was greater than that of fatal PE (69 vs 19 deaths; OR, 3.64; 95% CI, 2.22-6.20). The higher frequency of fatal bleeding compared with fatal PE from days 8 to 90 appeared to be confined to patients who were aged 65 60 years. Multivariate analysis showed that patient age was independently associated with an increased risk of death from bleeding during the first 3 months: every 10 years the OR increased by 1.37 (95% CI, 1.12-1.67).
CONCLUSIONS:
During the first week of treatment, the risk of fatal bleeding and fatal PE were similar. Then, particularly in patients who were aged 65 60 years, the risk of dying from bleeding exceeded the risk of dying from PE
Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism
Long-term therapy with low-molecular-weight heparin (LMWH) is the treatment of choice for cancer patients with venous thromboembolism (VTE). However, the ideal doses of LMWH have not been thoroughly studied. We used the RIETE Registry data to assess the influence of the daily LMWH dosage on outcome during the first three months after VTE. We used propensity score-matching to compare patients who received <150 vs. those receiving 65150 UI/kg/day LMWH. Up to July 2010, 3,222 cancer patients with VTE received long-term therapy with fixed doses of LMWH. Of these, 1,472 (46%) received <150 IU/kg/day (mean, 112 \ub1 28), and 1,750 received 65150 IU/kg/day (mean, 184 \ub1 32). Results of the propensity score matching involved 1269 matched pairs. During follow-up, the incidence of pulmonary embolism (PE) recurrences was similar (1.2% vs. 1.9%), but patients receiving <150 IU/kg/day LMWH had a lower incidence of fatal PE than those treated with 65150 IU/kg/day (0.2% vs. 1.0%; p=0.004). Multivariate analysis confirmed that patients receiving <150 IU/kg/day LMWH had a lower risk for fatal PE (odds ratio [OR]: 0.2; 95% confidence interval [CI]: 0.06-0.8) and for major bleeding (OR: 0.6; 95% CI: 0.3-1.0) than those treated with 65150 IU/kg/day. In real life, one in every two cancer patients with VTE received lower doses of LMWH than those used in randomised trials, with large variations from patient to patient. Unexpectedly, patients treated with <150 IU/kg/day LMWH had fewer fatal PE cases and fewer major bleeding events than those receiving 65150 IU/kg/day LMWH. This finding, however, should be validated in prospective clinical trials
Clinical significance of a negative D-dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry
Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry
BACKGROUND:
Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may induce therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in COPD patients.
METHODS:
COPD patients included in the on-going world-wide RIETE Registry were studied. The rate of pulmonary embolism (PE), major bleeding and death during the first 3 months in COPD patients were compared according to their initial clinical presentation (acute PE or deep vein thrombosis (DVT)).
RESULTS:
Of the 4036 COPD patients included, 2452 (61%; 95% CI: 59.2-62.3) initially presented with PE. PE as the first VTE recurrence occurred in 116 patients, major bleeding in 101 patients and mortality in 443 patients (Fatal PE: first cause of death). Multivariate analysis confirmed that presenting with PE was associated with higher risk of VTE recurrence as PE (OR, 2.04; 95% CI: 1.11-3.72) and higher risk of fatal PE (OR, 7.77; 95% CI: 2.92-15.7).
CONCLUSIONS:
COPD patients presenting with PE have an increased risk for PE recurrences and fatal PE compared with those presenting with DVT alone. More efficient therapy is needed in this subtype of patients